We are pleased to announce that AcariaHealth, a national comprehensive specialty pharmacy, has been chosen by Verona Pharma as a limited distribution pharmacy partner for OHTUVAYRE™ (ensifentrine). Approved by the U.S. Food and Drug Administration
(FDA), OHTUVAYRE™ is a pioneering maintenance treatment for chronic obstructive pulmonary disease (COPD) in adult patients. It acts as a selective dual inhibitor of phosphodiesterase 3 and phosphodiesterase 4 (PDE3 and PDE4), offering a novel approach that combines bronchodilator and non-steroidal anti-inflammatory effects in one treatment.

COPD, characterized by chronic inflammation in the lungs that obstructs airflow, manifests with symptoms like difficulty breathing, coughing, mucus production, and wheezing, as described by the Mayo Clinic. Emphysema and chronic bronchitis are the two primary conditions contributing to this debilitating disease.

As a trusted healthcare partner, AcariaHealth remains dedicated to transforming lives with compassionate care. We ensure timely medication delivery, provide ongoing assistance, and deliver superior patient care throughout the treatment journey. Patients and healthcare providers can rely on AcariaHealth for consistent quality service and support.

Download the referral form.

For more information about OHTUVAYRE, please see the OHTUVAYRE Full Prescribing Information or visit ohtuvayre.com. Additional information for healthcare professionals can be found at ohtuvayrehcp.com.

Catch the latest news and updates from AcariaHealth! Follow us on LinkedIn to stay informed about important announcements and industry insights.